Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells.

Ventura A, Vassall A, Yurter A, Robinson E, Filler R, Hanlon D, Meeth K, Ezaldein H, Girardi M, Sobolev O, Bosenberg MW, Edelson RL.

J Vis Exp. 2019 May 17;(147). doi: 10.3791/59370.

PMID:
31157760
2.

Increased Serine Synthesis Provides an Advantage for Tumors Arising in Tissues Where Serine Levels Are Limiting.

Sullivan MR, Mattaini KR, Dennstedt EA, Nguyen AA, Sivanand S, Reilly MF, Meeth K, Muir A, Darnell AM, Bosenberg MW, Lewis CA, Vander Heiden MG.

Cell Metab. 2019 Jun 4;29(6):1410-1421.e4. doi: 10.1016/j.cmet.2019.02.015. Epub 2019 Mar 21.

PMID:
30905671
3.

A novel immunogenic mouse model of melanoma for the preclinical assessment of combination targeted and immune-based therapy.

Lelliott EJ, Cullinane C, Martin CA, Walker R, Ramsbottom KM, Souza-Fonseca-Guimaraes F, Abuhammad S, Michie J, Kirby L, Young RJ, Slater A, Lau P, Meeth K, Oliaro J, Haynes N, McArthur GA, Sheppard KE.

Sci Rep. 2019 Feb 4;9(1):1225. doi: 10.1038/s41598-018-37883-y.

4.

Extracorporeal Photochemotherapy Drives Monocyte-to-Dendritic Cell Maturation to Induce Anticancer Immunity.

Ventura A, Vassall A, Robinson E, Filler R, Hanlon D, Meeth K, Ezaldein H, Girardi M, Sobolev O, Bosenberg MW, Edelson RL.

Cancer Res. 2018 Jul 15;78(14):4045-4058. doi: 10.1158/0008-5472.CAN-18-0171. Epub 2018 May 15.

PMID:
29764863
5.

Myeloid-targeted immunotherapies act in synergy to induce inflammation and antitumor immunity.

Perry CJ, Muñoz-Rojas AR, Meeth KM, Kellman LN, Amezquita RA, Thakral D, Du VY, Wang JX, Damsky W, Kuhlmann AL, Sher JW, Bosenberg M, Miller-Jensen K, Kaech SM.

J Exp Med. 2018 Mar 5;215(3):877-893. doi: 10.1084/jem.20171435. Epub 2018 Feb 7.

6.

DKK2 imparts tumor immunity evasion through β-catenin-independent suppression of cytotoxic immune-cell activation.

Xiao Q, Wu J, Wang WJ, Chen S, Zheng Y, Yu X, Meeth K, Sahraei M, Bothwell ALM, Chen L, Bosenberg M, Chen J, Sexl V, Sun L, Li L, Tang W, Wu D.

Nat Med. 2018 Mar;24(3):262-270. doi: 10.1038/nm.4496. Epub 2018 Feb 12.

7.

The DNA Methylcytosine Dioxygenase Tet2 Sustains Immunosuppressive Function of Tumor-Infiltrating Myeloid Cells to Promote Melanoma Progression.

Pan W, Zhu S, Qu K, Meeth K, Cheng J, He K, Ma H, Liao Y, Wen X, Roden C, Tobiasova Z, Wei Z, Zhao J, Liu J, Zheng J, Guo B, Khan SA, Bosenberg M, Flavell RA, Lu J.

Immunity. 2017 Aug 15;47(2):284-297.e5. doi: 10.1016/j.immuni.2017.07.020.

8.

Stem cell-released oncolytic herpes simplex virus has therapeutic efficacy in brain metastatic melanomas.

Du W, Seah I, Bougazzoul O, Choi G, Meeth K, Bosenberg MW, Wakimoto H, Fisher D, Shah K.

Proc Natl Acad Sci U S A. 2017 Jul 25;114(30):E6157-E6165. doi: 10.1073/pnas.1700363114. Epub 2017 Jul 14.

9.

UV-induced somatic mutations elicit a functional T cell response in the YUMMER1.7 mouse melanoma model.

Wang J, Perry CJ, Meeth K, Thakral D, Damsky W, Micevic G, Kaech S, Blenman K, Bosenberg M.

Pigment Cell Melanoma Res. 2017 Jul;30(4):428-435. doi: 10.1111/pcmr.12591. Epub 2017 Jun 8.

10.

Response to Programmed Cell Death-1 Blockade in a Murine Melanoma Syngeneic Model Requires Costimulation, CD4, and CD8 T Cells.

Homet Moreno B, Zaretsky JM, Garcia-Diaz A, Tsoi J, Parisi G, Robert L, Meeth K, Ndoye A, Bosenberg M, Weeraratna AT, Graeber TG, Comin-Anduix B, Hu-Lieskovan S, Ribas A.

Cancer Immunol Res. 2016 Oct;4(10):845-857. Epub 2016 Sep 2.

11.

Corrigendum: sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance.

Kaur A, Webster MR, Marchbank K, Behera R, Ndoye A, Kugel CH, Dang VM, Appleton J, O'Connell MP, Cheng P, Valiga AA, Morissette R, McDonnell NB, Ferrucci L, Kossenkov AV, Meeth K, Tang HY, Yin X, Wood WH, Lehrmann E, Becker KG, Flaherty KT, Frederick DT, Wargo JA, Cooper ZA, Tetzlaff MT, Hudgens C, Aird KM, Zhang R, Xu X, Liu Q, Bartlett E, Karakousis G, Eroglu Z, Lo RS, Chan M, Menzies AM, Long GV, Johnson DB, Sosman J, Schilling B, Schadendorf D, Speicher DW, Bosenberg M, Ribas A, Weeraratna AT.

Nature. 2016 Sep 8;537(7619):254. doi: 10.1038/nature18939. Epub 2016 Jul 6. No abstract available.

PMID:
27383789
12.

The YUMM lines: a series of congenic mouse melanoma cell lines with defined genetic alterations.

Meeth K, Wang JX, Micevic G, Damsky W, Bosenberg MW.

Pigment Cell Melanoma Res. 2016 Sep;29(5):590-7. doi: 10.1111/pcmr.12498. Epub 2016 Aug 3.

13.

Co-inhibition of colony stimulating factor-1 receptor and BRAF oncogene in mouse models of BRAFV600E melanoma.

Ngiow SF, Meeth KM, Stannard K, Barkauskas DS, Bollag G, Bosenberg M, Smyth MJ.

Oncoimmunology. 2015 Dec 10;5(3):e1089381. eCollection 2016 Mar.

14.

sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance.

Kaur A, Webster MR, Marchbank K, Behera R, Ndoye A, Kugel CH 3rd, Dang VM, Appleton J, O'Connell MP, Cheng P, Valiga AA, Morissette R, McDonnell NB, Ferrucci L, Kossenkov AV, Meeth K, Tang HY, Yin X, Wood WH 3rd, Lehrmann E, Becker KG, Flaherty KT, Frederick DT, Wargo JA, Cooper ZA, Tetzlaff MT, Hudgens C, Aird KM, Zhang R, Xu X, Liu Q, Bartlett E, Karakousis G, Eroglu Z, Lo RS, Chan M, Menzies AM, Long GV, Johnson DB, Sosman J, Schilling B, Schadendorf D, Speicher DW, Bosenberg M, Ribas A, Weeraratna AT.

Nature. 2016 Apr 14;532(7598):250-4. doi: 10.1038/nature17392. Epub 2016 Apr 4.

15.

DNMT3b Modulates Melanoma Growth by Controlling Levels of mTORC2 Component RICTOR.

Micevic G, Muthusamy V, Damsky W, Theodosakis N, Liu X, Meeth K, Wingrove E, Santhanakrishnan M, Bosenberg M.

Cell Rep. 2016 Mar 8;14(9):2180-2192. doi: 10.1016/j.celrep.2016.02.010. Epub 2016 Feb 25.

16.

BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume.

Theodosakis N, Held MA, Marzuka-Alcala A, Meeth KM, Micevic G, Long GV, Scolyer RA, Stern DF, Bosenberg MW.

Mol Cancer Ther. 2015 Jul;14(7):1680-92. doi: 10.1158/1535-7163.MCT-15-0080. Epub 2015 May 6.

17.

The broad-spectrum receptor tyrosine kinase inhibitor dovitinib suppresses growth of BRAF-mutant melanoma cells in combination with other signaling pathway inhibitors.

Langdon CG, Held MA, Platt JT, Meeth K, Iyidogan P, Mamillapalli R, Koo AB, Klein M, Liu Z, Bosenberg MW, Stern DF.

Pigment Cell Melanoma Res. 2015 Jul;28(4):417-30. doi: 10.1111/pcmr.12376. Epub 2015 May 6.

18.

PDK1 and SGK3 Contribute to the Growth of BRAF-Mutant Melanomas and Are Potential Therapeutic Targets.

Scortegagna M, Lau E, Zhang T, Feng Y, Sereduk C, Yin H, De SK, Meeth K, Platt JT, Langdon CG, Halaban R, Pellecchia M, Davies MA, Brown K, Stern DF, Bosenberg M, Ronai ZA.

Cancer Res. 2015 Apr 1;75(7):1399-412. doi: 10.1158/0008-5472.CAN-14-2785. Epub 2015 Feb 24.

19.

mTORC1 activation blocks BrafV600E-induced growth arrest but is insufficient for melanoma formation.

Damsky W, Micevic G, Meeth K, Muthusamy V, Curley DP, Santhanakrishnan M, Erdelyi I, Platt JT, Huang L, Theodosakis N, Zaidi MR, Tighe S, Davies MA, Dankort D, McMahon M, Merlino G, Bardeesy N, Bosenberg M.

Cancer Cell. 2015 Jan 12;27(1):41-56. doi: 10.1016/j.ccell.2014.11.014.

20.

Immune-based antitumor effects of BRAF inhibitors rely on signaling by CD40L and IFNγ.

Ho PC, Meeth KM, Tsui YC, Srivastava B, Bosenberg MW, Kaech SM.

Cancer Res. 2014 Jun 15;74(12):3205-17. doi: 10.1158/0008-5472.CAN-13-3461. Epub 2014 Apr 15.

21.

Structure of the Rtt109-AcCoA/Vps75 complex and implications for chaperone-mediated histone acetylation.

Tang Y, Holbert MA, Delgoshaie N, Wurtele H, Guillemette B, Meeth K, Yuan H, Drogaris P, Lee EH, Durette C, Thibault P, Verreault A, Cole PA, Marmorstein R.

Structure. 2011 Feb 9;19(2):221-31. doi: 10.1016/j.str.2010.12.012. Epub 2011 Jan 20.

22.

Site-specific introduction of an acetyl-lysine mimic into peptides and proteins by cysteine alkylation.

Huang R, Holbert MA, Tarrant MK, Curtet S, Colquhoun DR, Dancy BM, Dancy BC, Hwang Y, Tang Y, Meeth K, Marmorstein R, Cole RN, Khochbin S, Cole PA.

J Am Chem Soc. 2010 Jul 28;132(29):9986-7. doi: 10.1021/ja103954u.

23.

Structure of Vps75 and implications for histone chaperone function.

Tang Y, Meeth K, Jiang E, Luo C, Marmorstein R.

Proc Natl Acad Sci U S A. 2008 Aug 26;105(34):12206-11. doi: 10.1073/pnas.0802393105. Epub 2008 Aug 22.

24.

Fungal Rtt109 histone acetyltransferase is an unexpected structural homolog of metazoan p300/CBP.

Tang Y, Holbert MA, Wurtele H, Meeth K, Rocha W, Gharib M, Jiang E, Thibault P, Verreault A, Cole PA, Marmorstein R.

Nat Struct Mol Biol. 2008 Jul;15(7):738-45. doi: 10.1038/nsmb.1448. Epub 2008 Jun 22. Erratum in: Nat Struct Mol Biol. 2008 Sep;15(9):998. Verrault, Alain [corrected to Verreault, Alain].

Supplemental Content

Support Center